These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37977244)

  • 41. Mesenteric adipose tissue B lymphocytes promote local and hepatic inflammation in non-alcoholic fatty liver disease mice.
    Wu Z; Xu J; Tan J; Song Y; Liu L; Zhang F; Zhang Y; Li X; Chi Y; Liu Y
    J Cell Mol Med; 2019 May; 23(5):3375-3385. PubMed ID: 30772951
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.
    Nati M; Chung KJ; Chavakis T
    J Innate Immun; 2022; 14(1):31-41. PubMed ID: 34515137
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liver macrophages show an immunotolerance phenotype in nonalcoholic fatty liver combined with
    Guo L; Liu Y; Chen Y; Xu J; Liu Y
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2023 Aug; 41(4):385-394. PubMed ID: 37474470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis.
    Jin K; Shi Y; Zhang H; Zhangyuan G; Wang F; Li S; Chen C; Zhang J; Wang H; Zhang W; Sun B
    J Hepatol; 2023 Aug; 79(2):403-416. PubMed ID: 37040844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Multifaceted Roles of Macrophages in NAFLD Pathogenesis.
    Vonderlin J; Chavakis T; Sieweke M; Tacke F
    Cell Mol Gastroenterol Hepatol; 2023; 15(6):1311-1324. PubMed ID: 36907380
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.
    Milić S; Lulić D; Štimac D
    World J Gastroenterol; 2014 Jul; 20(28):9330-7. PubMed ID: 25071327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of NALPs in adipose and the fibrotic progression of non-alcoholic fatty liver disease in obese subjects.
    Mehta R; Neupane A; Wang L; Goodman Z; Baranova A; Younossi ZM
    BMC Gastroenterol; 2014 Dec; 14():208. PubMed ID: 25512222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exercise of high intensity ameliorates hepatic inflammation and the progression of NASH.
    Fredrickson G; Barrow F; Dietsche K; Parthiban P; Khan S; Robert S; Demirchian M; Rhoades H; Wang H; Adeyi O; Revelo XS
    Mol Metab; 2021 Nov; 53():101270. PubMed ID: 34118476
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatic metabolic adaptation and adipose tissue expansion are altered in mice with steatohepatitis induced by high-fat high sucrose diet.
    Baiges-Gaya G; Fernández-Arroyo S; Luciano-Mateo F; Cabré N; Rodríguez-Tomàs E; Hernández-Aguilera A; Castañé H; Romeu M; Nogués MR; Camps J; Joven J
    J Nutr Biochem; 2021 Mar; 89():108559. PubMed ID: 33264665
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
    Qing J; Ren Y; Zhang Y; Yan M; Zhang H; Wu D; Ma Y; Chen Y; Huang X; Wu Q; Mazhar M; Wang L; Liu J; Ding BS; Cao Z
    J Hepatol; 2022 Feb; 76(2):394-406. PubMed ID: 34648896
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease.
    Pafili K; Kahl S; Mastrototaro L; Strassburger K; Pesta D; Herder C; Pützer J; Dewidar B; Hendlinger M; Granata C; Saatmann N; Yavas A; Gancheva S; Heilmann G; Esposito I; Schlensak M; Roden M
    J Hepatol; 2022 Dec; 77(6):1504-1514. PubMed ID: 35988689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Associations Among Adipose Tissue Immunology, Inflammation, Exosomes and Insulin Sensitivity in People With Obesity and Nonalcoholic Fatty Liver Disease.
    Fuchs A; Samovski D; Smith GI; Cifarelli V; Farabi SS; Yoshino J; Pietka T; Chang SW; Ghosh S; Myckatyn TM; Klein S
    Gastroenterology; 2021 Sep; 161(3):968-981.e12. PubMed ID: 34004161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kazankov K; Jørgensen SMD; Thomsen KL; Møller HJ; Vilstrup H; George J; Schuppan D; Grønbæk H
    Nat Rev Gastroenterol Hepatol; 2019 Mar; 16(3):145-159. PubMed ID: 30482910
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
    de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
    J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease.
    Cimini FA; Barchetta I; Carotti S; Bertoccini L; Baroni MG; Vespasiani-Gentilucci U; Cavallo MG; Morini S
    World J Gastroenterol; 2017 May; 23(19):3407-3417. PubMed ID: 28596677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Atypical Cannabinoid Abn-CBD Reduces Inflammation and Protects Liver, Pancreas, and Adipose Tissue in a Mouse Model of Prediabetes and Non-alcoholic Fatty Liver Disease.
    Romero-Zerbo SY; García-Fernández M; Espinosa-Jiménez V; Pozo-Morales M; Escamilla-Sánchez A; Sánchez-Salido L; Lara E; Cobo-Vuilleumier N; Rafacho A; Olveira G; Rojo-Martínez G; Gauthier BR; González-Mariscal I; Bermúdez-Silva FJ
    Front Endocrinol (Lausanne); 2020; 11():103. PubMed ID: 32210914
    [No Abstract]   [Full Text] [Related]  

  • 58. Role of CC chemokine receptor 9 in the progression of murine and human non-alcoholic steatohepatitis.
    Morikawa R; Nakamoto N; Amiya T; Chu PS; Koda Y; Teratani T; Suzuki T; Kurebayashi Y; Ueno A; Taniki N; Miyamoto K; Yamaguchi A; Shiba S; Katayama T; Yoshida K; Takada Y; Ishihara R; Ebinuma H; Sakamoto M; Kanai T
    J Hepatol; 2021 Mar; 74(3):511-521. PubMed ID: 33038434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stellate cell expression of SPARC-related modular calcium-binding protein 2 is associated with human non-alcoholic fatty liver disease severity.
    Larsen FT; Hansen D; Terkelsen MK; Bendixen SM; Avolio F; Wernberg CW; Lauridsen MM; Grønkjaer LL; Jacobsen BG; Klinggaard EG; Mandrup S; Di Caterino T; Siersbæk MS; Indira Chandran V; Graversen JH; Krag A; Grøntved L; Ravnskjaer K
    JHEP Rep; 2023 Feb; 5(2):100615. PubMed ID: 36687468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The metabolic triad of non-alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment.
    Cariou B
    Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():15-27. PubMed ID: 35014161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.